Background
Although reinfections in vaccinated individuals should theoretically be lighter than primary infections in vaccinated individuals, the clinical–epidemiological differences and their importance regarding public health between cases of COVID–19 reinfection with vaccination and cases of COVID–19 primary infection with vaccination are not known.
Objective
To compare the clinical–epidemiological characteristics of the cases of COVID–19 reinfection with the cases of COVID–19 primary infection with 1, 2 or 3 doses of vaccine, to assess whether there are differences in health utility applicable to clinical work in general medicine.
Methodology
Comparison of secondary data from two observational, longitudinal, and prospective studies: A study of COVID–19 reinfection cases with vaccine (1, 2 or booster), and a set of studies of COVID–19 primary infections in vaccinated people (1 dose, 2 dose or booster), both from 2021 to June 2022, conducted on the same population, in a general medicine office in Toledo, Spain. For the statistical analysis, the bivariate comparisons were used Chi Square test, with Yates correction or Fisher Exact Test when necessary
Results
We included 35 people with COVID–19 reinfection with vaccine (with 37 infections due to 2 cases with 2 reinfections: 2 women aged 17 and 19, with 2 and 1 dose of vaccine respectively), and 88 people with primary COVID–19 infections in vaccinated (1, dose, 2 doses 3 doses) from 2021 to June 2022. The cases of COVID–19 reinfection with vaccine vs. COVID–19 primary infections with vaccine, were younger, more women, with higher social–occupancy class, and with more chronic diseases of respiratory system. There were no significant differences by symptoms.
Conclusion
The cases of COVID–19 reinfection with vaccination vs. cases of COVID–19 primary infection with vaccine (1, 2 or 3 doses) are not differentiated by chronic diseases, except more chronic diseases of the respiratory system, nor by symptoms of infection, but by social variables, being younger, more women, with higher social–occupancy class, which probably associate other health behaviors. Given that in developed countries the majority of the population is vaccinated with at least one dose, if reinfections in vaccinated differ from primary infections in vaccinated in affecting a certain segment of the population, this could be the subject of special health measures public.
Keywords: COVID–19; SARS–CoV–2; Reinfections; COVID–19 Vaccine; Epidemiologicalcharacteristic; Secondary Analysis; General Practice.
A reinfection with severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) occurs when a person with COVID–19 recovers and acquires SARS–CoV–2 again. In the disease caused by the SARS–CoV–2 (COVID–19) it quickly became clear that naturally acquired immunity would not, in all cases, provide protection for months after the first infection [1]. After having presented COVID–19, most individuals will have some degree of protection, which is temporary because they may be susceptible to infection again; in fact, it has been found that 60% of patients still have SARS–CoV–2 antibodies at the time of reinfection diagnosis [2].
Therefore, coronavirus infection does not result in lifelong immunity, and reinfection is common. The natural course of coronavirus infection includes repeated exposure and repeated infection over a variable time course. Over time, SARS–CoV–2 is likely to transform into a seasonal coronavirus infection [3]. Evidence of infections with other seasonal coronaviruses suggests cycles of infection, with different coronavirus strains predominating every two to four years, and that complete immunity against symptomatic reinfection for at least a year if “reinfected” with the same strain, but only partial immunity occurs when exposed to a heterologous strain [3].
Data from vaccination studies show that protection declines over time, but lasts in most people for at least four months. Vaccination has been shown to be effective against all naturally circulating strains. Evidence continues to emerge on efficacy against the latest variant (omicron), although protection is definitely reduced. In any case, the immunity derived from vaccination diminishes over time [3], but these help protect against severe illness, hospitalizations, and death [4].
Primary infections in vaccinated people (who have some immunity to COVID–19) are generally less severe than primary infections in unvaccinated people (who have no immunity); therefore, hospitalization rates are lower among those vaccinated. Therefore, it is reasonable to assume that, in general, reinfections must be less severe than primary infections, since the person who ecomes reinfected will have some pre–existing immunity from their primary infection. And while immunity against coronavirus infection and the development of covid symptoms declines, protection against serious illness and death appears much longer lasting. So reinfections definitely seem less severe [5,6].
In this context, if the primary infection generates immunity in such a way that the reinfection would be milder than the primary infection, and the infected vaccinated would have a milder clinical picture than the unvaccinated, consequently, the reinfections in vaccinated should be milder than primary infections in vaccinated. So far, data on this topic is minimal. This study aims to provide data on this so that they can be of practical application at the level of general medicine.
This study compares data from two set of previous published studies:
The studies were conducted on the same population: patients seen in a general medicine office in Toledo, Spain, which has a list of 2,000 patients > 14 years of age (in Spain, the general practitioners [GPs] care for people > 14 years of age, except for exceptions requested by the child's family and accepted by the GP). The GPs in Spain work within the National Health System, which is public in nature, and are the gateway for all patients to the system, and each person is assigned a GP [12]. The methodology of both studies has been previously published [7–11]. This methodology will only be partially mentioned here, to avoid repetition.
Outcome of interest
To compare the clinical–epidemiological characteristics of the cases of COVID–19 reinfection with vaccination with the cases of COVID–19 primary infection with 1, 2 or 3 doses of vaccine, to assess whether there are differences in health utility applicable to clinical work in general medicine.
Definition of primary infection and reinfection
Primary infection was defined as the first positive polymerase chain reaction (PCR) or antigen test. Reinfection was defined as the first positive PCR or antigen test obtained at least 90 days after the primary infection [6].
Collected variables
Age; Sex; symptoms; severity of the disease (primoinfección y reinfección) [13], chronic diseases [14], classified according to the International Statistical Classification of Diseases and Health–Related Problems, CD–10 Version: 2019 [15]; social–occupancy class [16], and Health Care Workers.
Statistic analysis
The bivariate comparisons were performed using the Chi Square test (X2), X2 with Yates correction or Fisher Exact Test when necessary, (according to the number the expected cell totals).
Ethical aspects
Individual patient data is not used, but only aggregated statistical data.
It was included 35 people with COVID–19 reinfection with vaccine (1, 2 or 3 doses), with 37 infections due to 2 cases with 2 reinfections: 2 women aged 17 and 19, with 2 and 1 dose of vaccine, respectively, from 2020 to June 2022, and 88 people with primary COVID–19 infections in vaccinated (1, dose, 2 dose and booster) from 2021 to June 2022. The cases of COVID–19 reinfection with vaccine vs. COVID–19 primary infections with vaccine were younger, more female, with a higher social–occupancy class, and with more chronic diseases of the respiratory system. There were no significant differences by symptoms (Table 1, 2 & 3).
Main findings
We found that the cases of COVID–19 reinfection with vaccine vs. COVID–19 primary infections with vaccine, were younger, more women, with higher social–occupancy class, and with more chronic diseases of respiratory system. There were no significant differences by symptoms. These results suggest that it is the social variables (age, sex, social class) that differentiate the cases of covid reinfection from those of primary infection in vaccinated (1, 2 or 3 doses). Possibly, these social variables are associated with certain health behaviors.
Table 1: Comparison of COVID–19 Reinfections Versus Primary Infections with Vaccine (1, 2 or 3 Doses) from 2021 to June 2022.
Variables |
COVID–19 Reinfections with Vaccine (1, 2 or 3 Doses) from 2021 to June 2022 |
Primary Infections COVID–19 with Vaccine (1, 2 or 3 Doses) From 2021 to June 2022 |
Statistical Significance |
> = 65 years |
2 (6) |
22 (25) |
|
Women |
29 (83) |
47 (53) |
|
Social–occupancy class of patients (people with some type of labor specialization) |
15 (43) |
11 (12) |
|
Health Care Workers |
7 (20) |
20 (33) |
|
Moderate–severe severity of reinfection |
0 |
0 |
Fisher exact test= 1. NS |
Moderate–severe severity of primary infection |
3 (9) (pneumonias) |
5 (6) (pneumonias) |
Fisher exact test= 0.6869. NS |
Chronic diseases presence |
22 (63) |
57 (65) |
|
( ): Denotes percentages; NS: Not significant. |
Table 2: Comparison of Chronic Diseases in COVID–19 Reinfections Versus Primary Infections with Vaccine (1, 2 Or 3 Doses) from 2021 To June 2022.
Chronic Diseases* According to WHO, ICD–10 Groups |
COVID–19 Reinfections with Vaccine (1, 2 or 3 Doses) From 2021 to June 2022 |
Primary Infections COVID–19 with Vaccine (1, 2 or 3 Doses) from 2021 to June 2022 |
Statistical Significance |
–I Infectious |
0 |
0 |
Fisher exact test= 1. NS |
–II Neoplasms |
1 (2) |
6 (3) |
Fisher exact test= 1. NS |
–III Diseases of the blood |
0 |
4 (2) |
Fisher exact test= 0.5872. NS |
–IV Endocrine |
10 (17) |
39 (17) |
|
–V Mental |
3 (5) |
13 (6) |
|
–VI–VIII Nervous and Senses |
4 (7) |
25 (11) |
|
–IX Circulatory system |
5 (9) |
28 (12) |
|
–X Respiratory system |
10 (17) |
11 (5) |
X2 with Yates correction= 9.0128. p–=s .002681. Significant at p < .05. |
–XI Digestive system |
4 (7) |
32 (14) |
|
–XII Diseases of the skin |
3 (5) |
8 (3) |
Fisher exact test= 0.4644. NS |
–XIII Musculo–skeletal |
7 (12) |
36 (15) |
|
–XIV Genitourinary |
11 (19) |
30 (13) |
|
TOTAL chronic diseases** |
58 |
232 |
––– |
( ): Denotes percentages; NS: Not significant; *Patients could have more than one chronic disease. The percentages of chronic diseases are over the total of chronic diseases of symptomatic and asymptomatic patients. |
Table 3: Comparison of Symptoms in COVID–19 Reinfections Versus Primary Infections with Vaccine (1, 2 Or 3 Doses) from 2021 to June 2022.
Symptoms* According to WHO, ICD–10 Groups |
COVID–19 Reinfections with Vaccine (1, 2 or 3 Doses) from 2021 to June 2022 |
Primary Infections COVID–19 with Vaccine (1, 2 or 3 Doses) from 2021 to June 2022 |
Statistical Significance |
General (discomfort, asthenia, myalgia, fever, artralgias) |
37 (39) |
62 (30) |
|
Respiratory (cough, dyspnea, chest pain) |
26 (27) |
47 (23) |
X2= 0.7725. p= .379448. NS |
ENT (Anosmia / ageusia, odynophagia, rhinorrhea, pharyngeal dryness–mucus, epixtasis) |
23 (24) |
71 (34) |
X2= 3.0918. p= .07869. NS |
Digestive (anorexia, nausea / vomiting, diarrhea, abdominal pain) |
3 (3) |
10 (5) |
X2 with Yates correction= 0.1295. p=.718938. NS |
Neurological (headache, dizziness, mental confusion –brain fog) |
6 (6) |
17 (8) |
X2= 0.333. p= .563918. NS |
Psychiatric (Anxiety, insomnia) |
0 |
0 |
Fisher exact test= 1. NS |
Skin (chilblains, flictenas, rash) |
0 |
0 |
Fisher exact test= 1. NS |
Total symptoms* |
95 |
207 (100) |
––– |
( ): Denotes percentages; NS: Not significant; * Patients could have more than one symptom. The percentages are over the total of symptoms; **N=37 (35 people, with 37 infections, for 2 cases with 2 reinfections: 2 women aged 17 and 19, with 2 and 1 dose of vaccine respectively). |
As of January 2022, 60.5% of the world's population has received at least one dose of a COVID–19 vaccine. Vaccination rates continue to lag in low–income countries, where only 10% of the population have received at least one dose of a vaccine, while in high– and upper–middle–income countries, 77% of the population have received at least one dose of a vaccine [17].
In Spain, as of April 27, 2021, 23.7% of the population had received at least one dose [18]. And as of May 6, 2021, the percentage of vaccination with the complete schedule was 85.4% [19]. As of June 3, 2021, the percentage of vaccinated with 1 dose and with 2 doses was very high: 87.1% of vaccinated with one dose, and 85.6% of vaccinated with a complete regimen were reported [17]. In the community of Castilla–La Mancha (Spain), where this study was carried out, as of November 10, 2021, there were 76% with 2 doses and 79% with one dose [20]. In this way, the number of unvaccinated people (without any dose) was very low as the year 2021 progressed. In April 2022, in Spain there were only 6% of people without any dose [21].
Given that in developed countries the majority of the population is vaccinated with at least one dose of vaccine, if reinfections in vaccinated differ from primary infections in vaccinated in affecting a certain segment of the population (young women of low socioeconomic status) , this population could be the object of special public health measures.
Comparison with other studies
Vaccination may increase protection in previously infected persons [22]. It has been reported that vaccination after a previous infection may result in a further reduction in the risk of reinfection and hospitalization for up to 9 months [23]. That is, those who have better long–term immunity are those who were infected and then have been vaccinated. Likewise, the majority of patients with reinfection in non–vaccinated people had mild symptoms in both episodes [24]. Reinfections were 90% less likely to result in hospitalization or death than primary infections [6]. In general, most studies suggest that the second SARS–CoV–2 infection is milder than the first. In fact, that is what should be expected from an immunological point of view [5, 25–28].
A single prior infection provides similar protection against infection with omicron as two doses of vaccine, but such immunity will still not be 100 percent protective [5, 6]. It is recognized that the reinfection may be milder than the primary infection. However, this may depend on when the infection occurs. Alpha reinfections are estimated to have given people symptoms only 20 percent of the time, while delta reinfections caused symptoms in 44 percent of cases and omicron in 46 percent. It has also been reported that people reinfected with alpha were much less likely to have symptoms the second time compared to their primary infection. While delta reinfections were somewhat more likely to give people symptoms compared to their primary infection. With an omicron reinfection, the rate of symptoms was almost the same in reinfection and primary infection [5, 6].
Our study covers from 2021 to June 2022. In the January 2021 period, the alpha variant predominated, and from the summer–autumn of 2021 there was an increase in the delta variant and a significant decrease in the Alpha variant [29, 30]. In November 2021 there was an almost total hegemony of the circulation of the delta variant with high population vaccination coverage. Although research suggests that COVID–19 vaccines are slightly less effective against the delta variant, they appear to offer protection against serious illness [31]. In March 2022, the BA.2 lineage of the omicron variant of COVID–19 predominated in Spain; at that time the prevalence of the alpha variant was declining [32, 33]. While people infected with delta are at risk of developing severe lung disease, infection with omicron often causes milder symptoms, especially in vaccinated people [34]. In our study, the fact of comparing reinfections with primary infections during the same dates avoids the possible temporal bias due to the different variants.
In a systematic review of 17 cases of genetically confirmed COVID–19 reinfection, it was found that 69% of people had symptoms similar to those of their first episode, 19% had a more severe condition and 12% a milder one [35]. Other studies have already reported suspected reinfection rates in non–vaccinated were higher in females and people < 65 years [36, 37]. Our data on vaccinated people repeat the same findings.
It is recognized that people whose immune system is impaired, as well as those with conditions due to diabetes, cancer, HIV or another type of chronic disease, are more likely to suffer a reinfection by COVID–19. However, this depends on the immunity they have generated from the primary infection and/ or vaccination. It currently seems to be accepted that underlying chronic respiratory diseases increase the predisposition to re– infection [38]. In the same population of our study, it has been previously published that the presence of chronic respiratory diseases was a moderate risk factor [8]. In the case of respiratory diseases, specifically, it has been seen that the representation of people with COPD or asthma with COVID–19 in relation to the population prevalence is strikingly low, however, COPD is associated with a worse clinical course and with a higher mortality from COVID–19, as well as a higher risk of admission to the ICU [39].
Not all social groups have been exposed to SARS–CoV–2 in the same way. Studies in various countries around the world, including Spain, have shown that the cumulative incidence of primary infection for COVID–19 has been higher in people of a lower socioeconomic position, perhaps due to greater exposure to the virus in people with fewer resources, especially in the workplace and housing [40–43]. On the other hand, it has been reported that people living in highly deprived areas were more likely to have post–vaccination infection after their first dose of vaccine [43]. However, we found more reinfections vs primary infections in people with a higher socio–occupational level.
Strengths and weaknesses of the study
The cases of COVID–19 reinfection with vaccination vs. cases of COVID–19 primary infection with vaccine (1, 2 or 3 doses) are not differentiated by chronic diseases, except more chronic diseases of the respiratory system, nor by symptoms of infection, but by psychosocial variables, being younger, and more women, with higher social–occupancy class, which probably associate other health behaviors. Given that in developed countries the majority of the population is vaccinated with at least one dose of vaccine, if reinfections in vaccinated differ from primary infections in vaccinated in affecting a certain segment of the population, this people could be subject to special measures of public health.
None.
Author declares that there is no Conflict of interest.